Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Apr:110:97-98.
doi: 10.1016/j.ejim.2022.12.007. Epub 2022 Dec 16.

Timeline analysis of clinical severity of COVID-19 in the general population

Camilla Mattiuzzi  1 , Giuseppe Lippi  2
Affiliations
Comment

Timeline analysis of clinical severity of COVID-19 in the general population

Camilla Mattiuzzi et al. Eur J Intern Med. 2023 Apr.
No abstract available

Keywords: COVID-19; SARS-CoV-2; Severity.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors have no conflict of interest relating to this study.

Figures

Fig. 1
Fig. 1
Percentage of home isolations, coronavirus disease 2019 (COVID-19) hospitalizations with symptoms, COVID-19 hospitalizations in intensive care unit (ICU) and timeline of prevalence (i.e., ≥50% in sequenced specimens) of different SARS-CoV-2 variants in Italy, from February 1, 2021 to December 7, 2022.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Giacomelli A., Ridolfo A.L., Oreni L., Rizzardini G., Antinori S., group COVID-Sacco Study. Trend in the proportion of subjects with SARS-CoV-2 infection without COVID-19 specific symptoms among patients admitted to a COVID-19 referral hospital. Eur J Intern Med. 2022 Dec 5;(S0953–6205(22)00430–7) doi: 10.1016/j.ejim.2022.12.001. Epub ahead of print. - DOI - PMC - PubMed
    1. Istituto Superiore di Sanità. Sorveglianza integrata COVID-19. Available at: https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati. Last accessed, December 9, 2022.
    1. Mattiuzzi C., Henry B.M., Lippi G. COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529) variant: a light at the end of the tunnel? Int J Infect Dis. 2022;118:167–168. - PMC - PubMed
    1. Imai M., Ito M., Kiso M., Yamayoshi S., Uraki R., Fukushi S., et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. N Engl J Med. 2022 Dec 7 doi: 10.1056/NEJMc2214302. Epub ahead of print. - DOI - PMC - PubMed
    1. Kurhade C., Zou J., Xia H., Liu M., Chang H.C., Ren P., et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster. Nat Med. 2022 Dec 6 doi: 10.1038/s41591-022-02162-x. Epub ahead of print. - DOI - PubMed